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Ondansetron does not inhibit the analgesic effect of alfentanil
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Summary
5-Hydroxytryptamine (5-HT) causes antinocicep-
tion via presynaptic 5-HT3 (5-HT subtype 3)
receptors on primary afferent nociceptive neurones
in the spinal cord dorsal horn. Therefore,
ondansetron (a 5-HT3 receptor antagonist) may
increase the perception of a noxious stimulus or
decrease the effects of concurrently administered
antinociceptive drugs. Using a randomized, double-
blind, crossover study design, we have tested this
hypothesis in eight healthy volunteers who, on
three different days, received either ondansetron
and placebo, ondansetron and alfentanil or placebo
and alfentanil. Experimental pain was induced with
heat, cold, mechanical pressure and electrical
stimulation. Ondansetron alone did not change the
response to any of the experimental tests, but
alfentanil and the combination ondansetron-
alfentanil significantly changed the response com-
pared with ondansetron alone. There was no
difference between alfentanil alone and the com-
bination ondansetron-alfentanil. We conclude that
ondansetron does not change the response to
pressure, heat, cold or electrical nociceptive stimuli
or antagonize the analgesic effect of alfentanil. (Br.
J. Anaesth. 1994; 73: 326-330)
Key words
Analgesics opioid, alfentanil. Vomiting, antiemetics.
The new antiemetic drug, ondansetron, has selective
antagonistic effects on 5-hydroxytryptamine subtype
3 (5-HT3) receptors [1]. These are located both
peripherally (vagal nerve endings) and centrally
(chemoreceptor trigger zone) [2]. 5-HT causes
antinociception via presynaptic 5-HT3 receptors on
primary afferent nociceptive neurones in the spinal
cord dorsal horn [3]. Therefore, a 5-HT3 receptor
antagonist might increase the perception of a noxious
stimulus or decrease the effects of antinociceptive
drugs.
Glaum, Proudfit and Anderson [4] found that
intrathecal serotonin produced antinociception in
the rat and that this effect could be antagonized by
tropisetron, another selective 5-HT3 receptor an-
tagonist. In a clinical investigation, Pitkanen and co-
workers [5] studied the effect of tropisetron on
nausea and analgesia after intrathecal morphine and
could not find any effect of tropisetron on post-
operative pain.
The aim of the present study was to see if
ondansetron could reduce the analgesic effect of
alfentanil on experimentally induced pain. Exper-
imental methods have the advantage that pain can be
induced in a controlled, standardized way. Using
different stimulation modalities it is possible to
assess different aspects of pain perception [6,7].
Subjects and methods
We studied eight healthy volunteers (seven male, one
female, mean age 25 (range 20-28) yr) who were not
receiving any medication and did not have any
allergies. Written informed consent according to the
Helsinki Declaration was obtained and the study was
approved by the Ethics Committee of Arhus,
Denmark. On three different days, with an interval
of at least 2 days, the volunteers received one of the
following three regimes according to a randomized,
double-blind, crossover study design: ondansetron-
placebo: ondansetron 8 mg in 100 ml of saline i.v.
followed 40 min later by saline 0.06 ml kg"1 i.m.;
ondansetron-alfentanil: ondansetron 8 mg in 100 ml
of saline i.v. followed 40 min later by alfentanil
30 ng kg"1 i.m.; placebo-alfentanil: saline 100 ml i.v.
followed 40 min later by alfentanil 30 ug kg"1 i.m.
In order to avoid the circadian variation in pain
sensitivity [8], each volunteer was always tested at
the same time of the day. The pain tests were
explained to the volunteer and a trial testing of all
techniques was performed in order to familiarize the
volunteer with the procedures. Each test series lasted
about 15 min. After a baseline test series, the
volunteer received ondansetron or placebo (saline)
i.v. according to the randomization: 25 min elapsed
before the second test series was performed. Then
alfentanil or placebo (saline) was given i.m. and
15 min thereafter [9] the third test series was
performed. A last test series was performed 75 min
after the alfentanil-placebo injection. The following
experimental tests were applied to assess pain.
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ARGON LASER PAIN TOLERANCE
The volunteer rested comfortably and wore laser
protective goggles. The output from an argon laser
(Spectra Physics 168) was transmitted to the skin via
a single 1-mm quartz fibre. The beam of the fibre
diverges and was adjusted to 1 cm on the skin with a
spacer. The output was adjusted to 2 W (controlled
with an external power meter). A continuous stimu-
lus was applied to the dorsum of the left hand
(stimulation of the same area was avoided) and a
counter was started at the onset of the laser
stimulation. The time until the volunteer wanted the
stimulation to be stopped was defined as the pain
tolerance threshold. If the pain tolerance threshold
was not reached within 30 s, stimulation was dis-
continued (in order to avoid skin damage) and the
pain tolerance threshold in such cases was defined as
30 s.
ICE WATER TEST
A 2-min ice water test was used [10,11]. During
these 2 min, the right hand was immersed in ice
saturated water (1.5 +1.0 °C). Pain intensity was
rated continuously with an electronic visual analogue
scale (VAS) coupled to a pen recorder. The area
under the pain intensity-time curve was calculated.
If the pain was considered intolerable before 2 min
had elapsed, the volunteer could withdraw the hand,
and for calculation of the area under the curve, the
pain intensity at withdrawal was presumed constant
to the end of the 2-min period.
MECHANICAL PRESSURE PAIN DETECTION AND PAIN
TOLERANCE THRESHOLDS
Pressure pain detection and pain tolerance thresholds
were determined on the centre of the pulpa of the
third finger of the left hand with an electronic
pressure algometer (Somedic AB, Stockholm,
Sweden) [6,12,13]. A probe with a surface area of
0.28 cm2 was used and the pressure was increased at
30kPas"'. Pain detection threshold was defined as
the point when pressure turned into pain and pain
tolerance as the point when the volunteer did not
want the pressure to be increased further. For
determination of the pain detection threshold, the
mean of three consecutive measurements was used.
Pain tolerance thresholds were determined only
once, in order to avoid damage and hence
sensitization of the area.
NOCICEPTIVE FLEXOR REFLEX
The sural nerve was stimulated behind the right
lateral malleolus with a 25-ms train of five 0.25-ms
square-wave impulses through felt electrodes soaked
in saline (inter-electrode distance 3 cm). Electro-
myographic reflex responses were recorded with
surface electrodes placed midway over the biceps
femoris and rectus femoris. Eight reflexes were
recorded, averaged and the root mean square (RMS)
value in the 80-180-ms interval after the stimulus
was calculated. After each recording the volunteer
rated the perceived pain on a visual analogue scale.
Statistical analysis was performed with the soft-
ware package SigmaStat Ver 1.01 (Jandel Scientific
GmbH, Erkrath, Germany). For statistical analysis,
all values were calculated as percentage of baseline
values. Friedman's test for repeated measures analy-
sis of variance on ranks and the Student-
Newman-Keuls test for multiple comparison were
used to test for differences in the reactions to the pain
tests in the ondansetron—placebo group for the four
tests and to determine differences between the
ondansetron-placebo, ondansetron-alfentanil and
placebo-alfentanil groups at the testing performed
15 min after administration of alfentanil or placebo
i.m. For calculation of confidence intervals, a
bootstrapping [14] (5000 replications of eight values)
was performed for each pain test and each measure-
ment. A similar bootstrapping was performed to
calculate the difference (and confidence intervals)
between the ondansetron-alfentanil and placebo-
alfentanil groups. To test the validity of the
experimental pain tests, the reactions of the
placebo-alfentanil group to the tests 15 min after
administration of alfentanil i.m. were analysed and
compared with baseline using Wilcoxon's signed
rank test. P < 0.05 was considered significant.
Results
There was no statistically significant change with
time in the response to any of the tests in the
ondansetron-placebo group (table 1). Fifteen
minutes after i.m. administration of alfentanil or
placebo, the reactions to the pain tests of the
placebo-alfentanil group and the ondansetron-
alfentanil group were significantly different com-
pared with the ondansetron-placebo group. The
difference in mechanical pressure pain thresholds
did not reach statistical significance. No differences
were found between the ondansetron-alfentanil
group and the placebo-alfentanil group (table 2).
Alfentanil alone significantly changed the reaction of
all of the experimental pain tests (except for
mechanical pressure pain threshold). The largest
changes in the median values were observed in the
pain tolerance to argon laser heat stimulation, which
increased by 42%, and in the ice water test, where
the area under the pain intensity-time curve was
reduced by 41 %. The VAS pain score to electrical
stimulation of the sural nerve was reduced by 25 %
and the RMS of the flexor reflex by 27 %. The pain
tolerance to mechanical pressure was increased by
18%.
Discussion
This study showed that ondansetron alone did not
change the reactions to any of the experimental pain
tests. The reactions were changed significantly by
alfentanil, but no significant difference could be
found between alfentanil given after placebo com-
pared with alfentanil given after ondansetron. The
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Table 1 Median (95 % confidence intervals calculated with the bootstrapping method) results of the experimental
pain tests in the ondansetron-placebo (O-P), ondansetron-alfentanil (O-A) and placebo-alfentanil (P-A) groups.
Values are expressed as percentage change from baseline (100%). *P < 0.05 compared with O-P group
Pain test 25 min 55 min 115 min
Heat pain tolerance
O-P
O-A
P-A
Ice water pain tolerance
O-P
O-A
P-A
Mechanical pressure pain detection
O-P
O-A
P-A
Mechanical pressure pain tolerance
O-P
O-A
P-A
Nociceptive flexor reflex (RMS)
O-P
O-A
P-A
VAS—electrical stimulation
O-P
O-A
P-A
94.8 (72.0-109.6)
93.3 (87.4-100.0)
100.9(100-127.3)
113.4(97.9-124.0)
96.6(92.0-119.3)
96.9(84.8-110.0)
104 (86.0-109.0)
96.7 (87.0-109.0)
95.3 (67.0-103.0)
94.8 (92.0-102.0)
99.6(90.0-123.5)
91.5(86.0-95.0)
85.8 (52.3-127.9)
83.0 (52.8-105.0)
98.0 (88.6-142.2)
101.3(92.4-120.7)
105.2 (97.2-120.0)
100.0(100.0-118.5)
95.3 (67.3-100.0)
115.0(100.0-144.2)*
135.8 (100.0-205.0)*
102.5(86.5-119.0)
48.8(21.2-84.2)*
60.0 (12.2-73.0)*
95.5 (93.0-98.0)
138.1 (116.0-156.0)
121.7(101.0-144.0)
97.9(91.0-119.0)
128.4(110.0-182.0)*
115.7(102.0-168.0)*
65.5 (49.6-117.5)
35.8 (22.8-79.9)*
47.9 (19.8-76.5)*
100.2(75.0-113.0)
57.7 (37.0-80.3)*
75.5 (39.4-97.5)*
87.3 (80.7-100.0)
89.4 (67.9-100.0)
100.0(83.7-129.3)
105.4 (97.7-123.5)
100.2(83.0-115.7)
93.1 (87.4-99.4)
97.4(87.0-117.0)
98.6(80.0-116.0)
84.7(71.0-95.0)
97.5(75.0-117.0)
104.6 (93.0-124.0)
102.2(85.0-121.0)
89.9(79.2-124.4)
75.4(39.8-104.2)
75.9(51.9-135.1)
100.0(89.6-120.5)
76.9(74.6-127.2)
112.7(96.6-121.0)
Table 2 Comparison between the ondansetron—alfentanil
(O-A) and placebo-alfentanil (P-A) groups for each pain test at
55 min. All values were calculated using the bootstrapping
method and are median (95 % confidence intervals) of the
difference between the two groups
Pain test DifT. (O-A minus P-A)
Heat pain tolerance
Ice water pain tolerance
Pressure pain detection
Pressure pain tolerance
Nociceptive flexor reflex (RMS)
VAS—electrical stimulation
-11.2 (-64.7-18.1)
1.9 (-12.4-28.4)
17.5 (-32.0-57.0)
24.0 (-58.0-66.0)
9.3 (-16.6-22.2)
-4.5 (-24.3-16.8)
hypothesis that the 5-HT3 receptor antagonist
ondansetron antagonizes antinociception was not
supported by the present study.
We studied only eight volunteers, repeatedly, and
although the variances of the measured variables
were generally not large, the possibility of a type II
error must be considered. However, the small
differences between ondansetron and placebo varied
in direction in the various tests. The increased heat
pain tolerance after alfentanil was reduced slightly
by pretreatment with ondansetron, whereas
ondansetron caused a slight additional effect on the
alfentanil-induced increase in tolerance to mech-
anical pressure pain, electrically induced pain and
decrease in cold pain. Furthermore, a bootstrapping
analysis of the difference between the ondansetron-
alfentanil and the placebo-alfentanil groups at
55 min also showed a non-significant difference
between the two groups, as zero is included in the
confidence interval for all tests. These findings
support our conclusion that ondansetron cannot
have a major influence on antinociception in acute
pain.
This conclusion is also supported by other studies.
Hammond [15] reviewed studies examining the effect
of selective alterations in serotonergic systems or
pathways on morphine-induced antinociception and
found very little consensus on the role of serotonergic
neurones in morphine-induced antinociception.
Dershwitz and co-workers [16] studied the effect of
ondansetron on opioid-induced ventilatory depres-
sion and sedation during steady state infusion of
alfentanil and found that ondansetron did not
produce any change in ventilatory depression or
sedation.
In several clinical studies where ondansetron was
used to prevent postoperative nausea and vomiting
(PONV), no increase could be found in the amount
of opioid medication administered to the group
receiving ondansetron compared with placebo
[Glaxo database, personal communication]. Leeser
and Lip [17] gave ondansetron 16 mg orally before
operation, followed by the same dose after operation,
8 h after the first dose, and found no difference in the
total opioid analgesic doses given during the first
24 h to the ondansetron-treated group compared
with the placebo group. However, ondansetron has a
relatively short half-life of about 3.5 h [18], and so an
antianalgesic effect of ondansetron in the first 6-12 h
might escape observation if only the total
accumulated dose within the first 24 h is recorded.
Scuderi and co-workers [19] studied ondansetron 1,
4 or 8 mg in the treatment of PONV after outpatient
surgery and found no increase in the percentage of
patients given opioids in the postanaesthetic care
unit in any of the ondansetron groups compared with
placebo. We used ondansetron 8 mg which is
considerably less than the 2x16 mg doses used in
the study of Leeser and Lip. Recent studies [19-21]
have shown that 4 mg and even 1 mg may be effective
in the prevention and treatment of PONV. Thus
ondansetron 8 mg used in the present study is a
clinically relevant dose.
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The antinociceptive or analgesic-sparing effect of
metoclopramide was observed by Lind and Breivik
[22] in 1970, and recently rediscovered by Rosenblatt
and co-workers [23,24]. Metoclopramide has a
partial 5-HT3 receptor antagonistic effect, but has a
more potent antidopaminergic effect. As
ondansetron is a selective 5-HT3 antagonist, the
antinociceptive effect of metoclopramide must be
caused by a mechanism different from its 5-HT3
antagonistic effect [25].
The pain tests used in the present study have been
shown to be specific and sensitive tests for various
antinociceptive drugs. The analgesic effects of
alfentanil were verified in the present study with
experimental pain tests in volunteers. Thermal
stimulation has been used to demonstrate the
analgesic effect of i.v. morphine [26], extradural
morphine [7], i.v. fentanyl [27] and i.m. alfentanil
[9]. In the latter study, brief argon laser pulses
(200 ms) covering a small area (3 mm diameter) were
used to determine pain detection thresholds. We
used a continuous laser light with a fixed intensity,
covering a larger area, and measured the time to pain
tolerance. The modified 2-min ice water test was
described by Jones and co-workers [11]; they found
the test to be sensitive to opioids. The pressure
algometer used in the present study has been
evaluated by Brennum and co-workers [12] and has
been used to demonstrate the analgesic effect of
extradural morphine [7] and i.v. morphine [13].
Wilier [28], and Chan and Dallaire [29] found a
linear relation between the amplitude of the no-
ciceptive flexor reflex and perceived pain. I.v.
morphine reduces the nociceptive reflex and the
associated pain report [30]. Extradural morphine
3 mg for postoperative pain relief resulted in a 40 %
decrease in the nociceptive reflex 30 min after
injection [31]. In the present study, alfentanil
30 ug kg"1 i.m. significantly changed the reaction to
all of the experimental pain tests, except for
mechanical pressure pain thresholds, thus support-
ing the validity of the pain tests at this dose of
alfentanil. The largest changes were observed in the
pain tolerance to argon laser heat stimulation and in
the ice water test. Smaller changes were observed
with electrical stimulation of the sural nerve and
with mechanical pressure. The nociceptive flexor
reflex is composed of both sensory and motor
components; alfentanil might affect not only the
sensory component.
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